Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenues, net $ 9,472 $ 3,840 $ 33,885 $ 9,351
Cost of revenues 5,495 2,798 16,515 6,615
Gross profit 3,977 1,042 17,370 2,736
Operating expenses:        
Diagnostic expenses 1,478 6,117
General and administration 5,938 1,552 14,713 3,875
Research and development 208 57 416 181
Total operating expenses 7,624 1,609 21,246 4,056
Loss from operations (3,647) (567) (3,876) (1,320)
Interest income, net 230 39 531 53
Interest expense (296) (41) (870) (41)
Change in fair value of investment securities (265) (101)
Loss from continuing operations (3,978) (569) (4,316) (1,308)
Discontinued Operations:        
Income from discontinued operations 161 161
Net loss (3,978) (408) (4,316) (1,147)
Other comprehensive loss:        
Unrealized loss on marketable debt securities (33) (8) (111) (2)
Total comprehensive loss $ (4,011) $ (416) $ (4,427) $ (1,149)
Basic and diluted earnings (loss) per share:        
Loss from continuing operations $ (0.26) $ (0.05) $ (0.29) $ (0.11)
Income from discontinued operations 0.01 0.01
Net loss per share $ (0.26) $ (0.04) $ (0.29) $ (0.10)
Weighted average common shares outstanding:        
Basic and diluted 15,439 11,604 15,055 11,593